HK Stock Market Move | JUNSHI BIO(01877) rose over 8% in the afternoon. The third largest shareholder did not reduce their holding as planned, and their ownership percentage remains at 5.79%.

JUNSHI BIO (01877) rose more than 8% in the afternoon, up 6.98% as of the time of writing, at HK$26.68, with a trading volume of HK$177 million. On the news front, JUNSHI BIO previously announced that its third largest shareholder, Shanghai Tan Ying Investment Partnership Enterprise, plans to reduce its shareholding by no more than 2% of the total share capital between January 13 and April 10, 2026. The latest announcement shows that as of the end of the reduction plan period, Shanghai Tan Ying has not sold any shares, and its shareholding percentage remains at 5.7914%. It is worth noting that JUNSHI BIO recently released its annual performance, with an annual operating income of RMB 2.498 billion, a year-on-year increase of 28.23%. Sales revenue of its core product, Tropilimab monoclonal antibody, also achieved a growth of over 40%. As of the date of the report disclosure, Tropilimab has obtained approval for 12 indications in mainland China, all included in the national medical insurance catalog, and has been approved for marketing in more than 40 countries and regions worldwide, including China, the United States, and Europe.